Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
The study will enroll patients with prior IO therapy (alone or in combination with
chemotherapy or in combination with other IO agents) regardless of the PD-L1 level, into a
non-randomized combination trial, with primary endpoint of disease control rate.